Avidity Biosciences GAAP EPS of -$1.27 misses by $0.16, revenue of $12.48M
Source: SeekingAlpha
2025-11-10 16:54:06 ET
More on Avidity Biosciences
- Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats
- Novartis' Avidity Deal: Growth Accretive, Multiple Gated By Execution
- Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
- Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
- Avidity stock surges on $12B Novartis deal
Read the full article on Seeking Alpha
For further details see:
Avidity Biosciences GAAP EPS of -$1.27 misses by $0.16, revenue of $12.48M
Avidity Biosciences Inc.
NASDAQ: RNA
RNA Trading
-3.96% G/L:
$13.95 Last:
365,705 Volume:
$14.47 Open:
RNA Latest News
February 27, 2026 09:19:00 am
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
February 26, 2026 04:02:00 pm
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 23, 2026 08:00:00 am
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
RNA Stock Data
$10,978,987,941
124,608,839
0.38%
98
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
